New monoclonals for cancer research
Nowadays, several approaches aim to understand the biology of diseases by identifying promising markers, which may provide effective novel therapies.
The identification of molecular biomarkers is unquestionably essential and urgent for an accurate prognosis and the development of critical therapeutic targets in cancer research. Therefore, we must expand our knowledge as a step toward the design of practical and safe treatments.
Atlas Antibodies released new PrecisA Monoclonals related to ovarian and glioma research.
Needs
- Specific and effective biomarkers able to identify early stages of the disease and reliable prognostic markers for predicting clinical responses as well as defining the divergent molecular pathways underlying the development of the disease.
- Protein-related data such as citations, application-specific validation and sequence information, and homology, are paramount in the buying process and the single biggest driver for antibody choice.
- A trusted source of data in order to feel confident in the purchase of new antibodies.
Why Atlas Antibodies?
- Atlas Antibodies continues searching for better early detection markers and new therapeutic targets.
- Over 12,000 product citations worldwide
- Application-specific Enhanced Validation
- Strong roots in the Human Protein Atlas
- Transparency & open-access data
Ovarian markers - new monoclonals antibodies
Ovarian cancer is the deadliest form of female gynecologic cancers causing more deaths than any other cancer of the female reproductive system.
Ovarian Cancers Markers White Paper
Gynecologic cancers originate In the female reproductive organs. The 5 main types of gynecologic cancers are cervical, ovarian, uterine, vaginal, and vulvar. Atlas Antibodies continues searching for better early detection markers and new therapeutic targets. This white paper presents our selected PrecisA Monoclonals TM and TripleA Polyclonals™ targeting ovarian cancers.
Therefore, there is a high demand to identify biomarkers specific to this disease for screening for early detection, as well as new therapeutic targets. The capacity of these biomarkers to predict the existence, stages, and associated therapeutic efficacy of ovarian cancer would enable improvements in the early diagnosis and survival of ovarian cancer patients.
Discover the right monoclonal for your research from the table below:
|
Product Name |
Protein Name |
Product ID |
Isotype |
Recommended Applications |
Interspecies Sequence Homology |
|
Anti-BCOR |
Bcl6 corepressor |
IgG2b |
IHC, ICC-IF |
Mouse 100% - Rat 100% |
|
|
Anti-FXYD5 |
Fxyd domain-containing ion transport regulator 5 |
IgG1 |
IHC |
Mouse 33% - Rat 31% |
|
|
IgG2b |
IHC |
Mouse 33% - Rat 31% |
|||
|
Anti-GREB1 |
Growth Regulation by Estrogen in breast cancer 1 |
IgG2a |
WB, IHC |
Mouse 85% - Rat 85% |
|
|
IgG1 |
IHC, ICC-IF |
Mouse 85% - Rat 85% |
|||
|
Anti-MLH3 |
Mutl homolog 3 |
IgG2b |
IHC, WB, ICC-IF |
Mouse 72% - Rat 72% |
|
|
IgG2a |
IHC, WB, ICC-IF |
Mouse 72% - Rat 72% |
|||
|
Anti-MSH2 |
Muts homolog 2 |
IgG2a |
IHC, WB, ICC-IF |
Mouse 95% - Rat 90% |
|
|
IgG2b |
IHC, WB, ICC-IF |
Mouse 95% - Rat 90% |
|||
|
IgG2b |
IHC, WB, ICC-IF |
Mouse 95% - Rat 90% |
|||
|
Anti-MSH3 |
Muts homolog 3 |
IgG1 |
IHC, WB, ICC-IF |
Mouse 100% - Rat 100% |
|
|
IgG2b |
IHC, WB, ICC-IF |
Mouse 100% - Rat 100% |
|||
|
Anti-MSH6 |
Muts homolog 6 |
IgG2b |
WB, IHC |
Mouse 86% - Rat 74% |
|
|
Anti-MSLN |
Mesothelin |
IgG1 |
WB, IHC |
Mouse 63% - Rat 62% |
|
|
IgG2a |
WB, IHC |
Mouse 63% - Rat 62% |
|||
|
IgG2b |
WB, IHC |
Mouse 63% - Rat 62% |
|||
|
Anti-SMARCA4 |
Swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
IgG1 |
WB, ICC-IF |
Mouse 100% - Rat 100% |
|
|
IgG1 |
IHC |
Mouse 100% - Rat 100% |
|||
|
Anti-SMARCB1 |
Swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 |
IgG1 |
WB, IHC |
Mouse 100% - Rat 100% |
|
|
IgG2b |
WB, IHC |
Mouse 100% - Rat 100% |
|||
|
IgG2a |
WB, IHC |
Mouse 100% - Rat 100% |
|||
|
IgG2a |
IHC, WB, ICC-IF |
Mouse 100% - Rat 100% |
Use a 10% discount with our promo code on FIRST purchase
>>>Get the code here
Choose and order directly on our website >>>
Glioma markers - new monoclonals antibodies
Gliomas are one of the most aggressive and lethal solid tumors of the central nervous system. Despite the alarming numbers, the molecular pathogenetic mechanisms of gliomas are not yet fully elucidated.
Glioma Markers White Paper
Gliomas are one of the most aggressive and lethal solid tumors of the central nervous system. Despite the alarming numbers, the molecular pathogenetic mechanisms of gliomas are not yet fully elucidated. This white paper highlights the glioma proteome with a list of relevant genes with favorable and unfavorable prognostic values in glioma and focuses on the glioma tumor microenvironment that may provide helpful insights when developing novel therapeutic strategies.
Nowadays, several approaches aim to understand the biology of the disease and identify promising markers, which may provide effective novel therapies.
Understanding the dynamic glioma tumor microenvironment is necessary for the development of new immunotherapeutic strategies.
Gliomas are well-known tumors at the molecular level. However, these advances have not been translated into therapeutic benefits for the patients.
Discover the right monoclonal for your research from the table below:
|
Product Name |
Protein Name |
Product ID |
Isotype |
Recommended Applications |
Interspecies Sequence Homology |
|
Anti-ADAM10 |
Adam metallopeptidase domain 10 |
IgG1 |
WB, IHC |
Mouse 100% - Rat 100% |
|
|
IgG1 |
WB, IHC |
Mouse 100% - Rat 100% |
|||
|
IgG2b |
IHC, ICC-IF |
Mouse 100% - Rat 100% |
|||
|
IgG2b |
IHC, ICC-IF |
Mouse 100% - Rat 100% |
|||
|
Anti-FOXO3 |
Forkhead box o3 |
IgG2a |
WB, IHC |
Mouse 100% - Rat 100% |
|
|
IgG2a |
IHC |
Mouse 100% - Rat 100% |
|||
|
Anti-IGFBP2 |
Insulin-like growth factor binding protein 2 |
IgG1 |
WB, IHC |
Mouse 68% - Rat 74% |
|
|
IgG2a |
IHC |
Mouse 68% - Rat 74% |
|||
|
Anti-IL33 |
Interleukin 33 |
IgG2b |
IHC, ICC-IF |
Mouse 48% - Rat 50% |
|
|
Anti-LGR5 |
Leucine-rich repeat-containing g protein-coupled receptor 5 |
IgG2a |
WB, IHC |
Mouse 91% - Rat 87% |
|
|
IgG1 |
IHC |
Mouse 91% - Rat 87% |
|||
|
Anti-PROX1 |
Prospero homeobox 1 |
IgG1 |
WB, IHC |
Mouse 100% - Rat 99% |
|
|
IgG1 |
ICC-IF |
Mouse 100% - Rat 99% |
|||
|
Anti-ZEB2 |
Zinc finger e-box binding homeobox 2 |
IgG1 |
IHC, WB, ICC-IF |
Mouse 95% - Rat 93% |
|
|
Anti-YAP1 |
Yes1 associated transcriptional regulator |
IgG2b |
IHC |
Mouse 95% - Rat 95% |
|
|
Anti-WNT5A
|
Wnt family member 5a |
IgG2a |
IHC |
Mouse 100% - Rat 100% |
PrecisA Monoclonals
PrecisA Monoclonals™, cultured in murine cell lines, are in-house developed precise, accurate and targeted mouse monoclonals validated for use in IHC, WB and ICC-IF.
At Atlas Antibodies we take special care in designing clones that recognize unique non-overlapping epitopes and/or isotypes. As a result, PrecisA Monoclonals offer premium performance in the approved applications. Using our stringent production process and characterization procedures, PrecisA Monoclonals ensure specificity, multiplexing opportunities, secured continuity, and a stable supply.